Paul Frohna

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

William J. Sandborn, Brian G. Feagan, Douglas C. Wolf et al. · New England Journal of Medicine · 2016 · 444 citations · Full text

RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis

Ikuo Hirano, Margaret H. Collins, Yehudith Assouline-Dayan et al. · Gastroenterology · 2018 · 258 citations · Full text

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

Jeffrey A. Cohen, Douglas L. Arnold, Amit Bar‐Or et al. · The Lancet Neurology · 2016 · 176 citations

Medicine, Pharmacology, Clinical Trials +7

UB‐311, a novel UBITh ^® amyloid β peptide vaccine for mild Alzheimer's disease

Chang Yi Wang, Pei‐Ning Wang, Ming‐Jang Chiu et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2017 · 139 citations · Full text

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Paul Frohna, Jianfeng Lu, Steve Eppler et al. · The Journal of Clinical Pharmacology · 2006 · 109 citations

Oral Bioavailability, Healthy Subjects, Pharmacological Study +14